The primary endpoint for the trial is overall survival and the study is designed to support full regulatory approvals around the world, according to the company.
Price: 2.96, Change: +0.04, Percent Change: +1.37
|Berenberg Bank Adjusts Kosmos Energy's Price Target ...|
|--RBC Capital Adjusts Sibanye Stillwater's Price Tar...|
|--RBC Lifts Vale to Sector Perform From Underperform...|
|--Nomura Cuts IQIYI's Price Target to $5.20 From $7....|
|--Nomura Adjusts Baidu's Price Target to $167 From $...|